ArticleAnimal models and experimental medicine2026
Zebrafish xenograft models as a fast platform for metastasis diagnosis and cisplatin response of head and neck squamous cell carcinoma.
Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundHead and neck squamous cell carcinoma (HNSCC) is characterized by clinically undetectable early metastasis and a poor prognosis at locally advanced and recurrent metastatic stages. Platinum-based resistance remains a major limitation to treatment efficacy. Currently, no reliable biomarkers are available to identify lymph node metastasis or to predict therapeutic sensitivity. Therefore, this study aimed to develop a predictive model to address these clinical challenges.
methodsFour cell lines (CAL-27, FaDu, Leuk1, NOEC) were employed to establish zebrafish cell-derived xenograft (zCDX) models and assess the differential metastatic potential. Surgical or biopsy samples from, respectively, 20 and 14 HNSCC patients were used for building and validating the zebrafish patient-derived xenograft (zPDX) models. Cisplatin-sensitive HNSCC cell lines (CAL-27 and FaDu) and their cisplatin-resistant sublines (CAL-27-DDP and FaDu-DDP) were established, and the differential responses to cisplatin were evaluated in both murine and zCDX models. Additionally, to assess the patient-specific therapeutic efficacy of cisplatin, zPDX models were generated from four patient-derived surgical specimens and a supplementary biopsy for preliminary validation.
resultsThe zebrafish xenograft model recapitulated the invasive phenotype of the HNSCC cell lines. The model distinguished between metastatic and non-metastatic disease with high accuracy (AUC = 0.98). It faithfully reproduced the cisplatin sensitivity and resistance patterns identified in corresponding in vitro and murine models. Moreover, it showed strong concordance with patient-specific cisplatin responses.
conclusionsThe zPDX model provides a rapid, efficient, clinically applicable platform for predicting metastasis and evaluating platinum-based therapy responses in HNSCC, facilitating the design of scientifically grounded personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.